[PDF][PDF] 《 根据CYP2D6, OPRM1 和COMT 基因型选择阿片类药物治疗方案的临床药物遗传学实施联盟指南》 解读
谢菡， 胡美玲， 葛卫红， 周玉皆， 王鑫梅 - 医药导报, 2023 - yydbzz.com
… Clinical pharmacogenetics implementation consortium guideline for CYP2D6ꎬOPRM1ꎬand
… of the genetically determined differences in morphine formation[J].Painꎬ1998ꎬ76(1/ 2):27-…
… of the genetically determined differences in morphine formation[J].Painꎬ1998ꎬ76(1/ 2):27-…
[HTML][HTML] 托莫西汀在注意力缺陷多动障碍患儿中的精准药学研究： CYP2D6 基因检测和治疗药物监测
符迪， 郭宏丽， 胡雅慧， 陈峰 - Chinese Journal of Contemporary …, 2023 - ncbi.nlm.nih.gov
… differences in the pediatric population. This article reviews the genetic factors influencing the
pharmacokinetic differences … 联盟（Clinical Pharmacogenetic Implementation Consortium，…
pharmacokinetic differences … 联盟（Clinical Pharmacogenetic Implementation Consortium，…
[HTML][HTML] 硫嘌呤类药物的遗传药理学研究及其在儿科相关疾病中的正确应用
郭宏丽， 胡雅慧， 夏颖， 龙佳奕… - 南京医科大学学报(自然科学 …, 2021 - jnmu.njmu.edu.cn
… Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing
based on TPMT and NUDT15 genotypes:2018 Update[J].Clin Pharmacol Therapeut,2019,105(5):…
based on TPMT and NUDT15 genotypes:2018 Update[J].Clin Pharmacol Therapeut,2019,105(5):…
[HTML][HTML] 基于药物代谢酶和转运体基因组学的药物精准治疗
周权， 余露山， 曾苏 - 药学学报, 2017 - html.rhhz.net
… 委员会(Clinical Pharmacogenetics Implementation Consortium, … 1 CPIC guideline for
applications of pharmacogenomics … CPIC: Clinical Pharmacogenetics Implementation Consortium; …
applications of pharmacogenomics … CPIC: Clinical Pharmacogenetics Implementation Consortium; …
氯吡格雷治疗急性脑梗死病人CYP2C19 基因多态性检测的临床意义
骆嵩， 杨丽娟， 屈洪党 - 蚌埠医学院学报, 2018 - xuebao.bbmc.edu.cn
… of which on the clinical outcome of ACI patients treated with conventional method combined
with antiplatelet was statistically analyzed.Results:The difference of the metablism type …
with antiplatelet was statistically analyzed.Results:The difference of the metablism type …
[PDF][PDF] 血小板功能检测或基因检测指导的双联抗血小板药物降阶治疗对行经皮冠状动脉介入治疗的急性冠脉综合征患者预后影响的Meta 分析
赵志刚， 雷梦杰， 王胜楠… - Journal of …, 2022 - boyuancaibian.oss-cn-beijing …
… compare the incidence of primary endpoint events (major adverse cardiovascular and
cerebrovascular events) , primary safety endpoint events (bleeding, significant clinical … difference …
cerebrovascular events) , primary safety endpoint events (bleeding, significant clinical … difference …
[PDF][PDF] 药物基因组学与临床药师*
刘飞， 辛华雯 - 医药导报, 2017 - yydbzz.com
… Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype
and … Comparison of the predictive abilities of pharmacogenetics-based warfarin dosing algori…
and … Comparison of the predictive abilities of pharmacogenetics-based warfarin dosing algori…
[HTML][HTML] 药物基因检测在PLA2R 相关性膜性肾病患者治疗中的效果
谭婷婷， 郑义侯， 李芸， 曾又佳 - Journal of Southern Medical …, 2023 - ncbi.nlm.nih.gov
… A2 receptor antibody, 24-h urine protein, and serum albumin levels were significantly
improved in pharmacogenetic testing group as compared with the control group (P < 0.05). …
improved in pharmacogenetic testing group as compared with the control group (P < 0.05). …
[PDF][PDF] 比较3 种类型的华法林维持剂量算法对东台地区汉族心房颤动患者国际标准化比值的达标率
陈蓉， 鲁振雯， 王席， 丁玺 - 临床与病理杂志, 2020 - cdn.amegroups.cn
… %, which achieved a significant improvement when compared with the IWPC model group
(45.0%), and the physician-defined group (31%), the difference was statistically significant (P<…
(45.0%), and the physician-defined group (31%), the difference was statistically significant (P<…
[PDF][PDF] 华法林标准用药监护模式的建立与临床应用*
丁英龙， 秦琼， 薛领， 周玲， 谢诚， 沈振亚， 缪丽燕 - 医药导报, 2022 - yydbzz.com
… pathway and comprehensive managementꎬwhich were embedded in the clinical
pharmacist workstation.Compared with the control groupꎬthe compliance with warfarin was …
pharmacist workstation.Compared with the control groupꎬthe compliance with warfarin was …